Vestergaard Frandsen Supports Women Deliver and the MDGs


By: Mikkel Vestergaard Frandsen, CEO of the Group Vestergaard Frandsen

I shared the stage on Sunday, 19 September with Dr. Imane Khachani of Morocco at the Women Deliver event on "Accelerating Action on the MDGs: Delivering for Girls, Women and Babies" at the Waldorf Astoria hotel in New York. At this important event, I spoke about the need to engage the private sector when developing solutions to addressing global public health issues. As a representative of the private sector, I wanted to highlight the fact that many companies, including Vestergaard Frandsen, want to be a partner in identifying and implementing solutions to improve the lives of girls and women. Read more...

The Girl Effect: The Clock is Ticking tells the story of girls creating a ripple impact of social and economic change on their families, communities and nations. Launched a few years ago, this compelling video showed the world the power of investing in girls. Last week, at the Clinton Global Initiative, the Girl Effect launched a new video that builds on the original message, and discusses important issues like child marriage and early pregnancy for adolescent girls.

Despite Progress, Universal Access to HIV Medicine Still Out of Reach

Earlier today, WHO, UNICEF and UNAIDS launched the report Towards universal access, the fourth report tracking progress made towards achieving universal access to HIV prevention, treatment and care by the end of 2010.  Significant strides have been made in the past year, particularly among the low and middle income countries:

  • 15 countries provided more than 80% of HIV-positive pregnant women with the services and medicines needed to prevent mother-to-child HIV transmission;
  • 14 countries provided HIV treatment to more than 80% of HIV-positive children ;
  • Eight countries have achieved universal access to antiretroviral treatment (ART) for adults.


Mifepristone and Misoprostol: 10 Years Later

Today is the ten-year anniversary of the U.S. Food and Drug Administration (FDA)'s approval of the use of the abortion drug mifepristone, also known as RU-486 or the "abortion pill", in combination with the second drug, misoprostol. Marketed as Mifeprix, this alternative to surgical abortion for terminating early pregnancies has seen a substantial increase in use in the past decade, allowing many women a choice between medication or a surgical procedure when seeking an early abortion. While the number of medication abortions and providers offering them increased, the total number of abortions performed in the U.S. declined. However, the expectation that abortion access would improve, especially in rural areas, was not realized, according to a Guttmacher Institute report released last year.

Click here for more information:
Facts on Induced Abortion in the United States
The incidence of abortion in the United States
The effect of mifepristone on abortion access

H4+ Group Advancing Progress and Announcing New Support for MDG5

By: Madeline Taskier, Partnership Coordinator for Women Deliver

Last week during the MDG Summit, the H4+ group gathered to present country successes in maternal health and to announce its next steps for MDG5. The H4+ official side event at the Unicef House, “Accelerating progress in achieving MDG5:  Trends and Lessons from countries,” brought together mission representatives and delegates from countries, development partners, donors, foundations, and non-governmental organizations. The H4+ group including Unicef, WHO, UNFPA, the World Bank, and UNAIDS currently supports maternal health programming in 26 priority countries. Read more...

 1 2 3 >  Last ›


Women Deliver 

588 Broadway, Suite 905
New York, NY 10012 USA

Tel: +1.646.695.9100
Fax: + 1 646.695.9145

Email: info [at]


Join the
Mailing List

Click here to join the mailing list.